牛牛AI助理已提取核心訊息
Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc. (CING), was involved in a transaction on 03/04/2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of insiders in the company's prospects.
Matthew Brams, EVP and Chief Medical Officer of Cingulate Inc. (CING), was involved in a transaction on 03/04/2024. The specific details of the transaction, such as the action type, status, number of shares, nature of shares, transaction price, and post-transaction holdings, were not disclosed in the announcement. This information is critical for investors to understand the potential impact on their investment and the confidence of insiders in the company's prospects.
Cingulate Inc.（CING）執行副總裁兼首席醫學官馬修·布拉姆斯於2024年4月3日參與了一筆交易。公告中未披露交易的具體細節，例如行動類型、狀態、股票數量、股票性質、交易價格和交易後持有量。這些信息對於投資者了解其投資的潛在影響以及內部人士對公司前景的信心至關重要。
Cingulate Inc.（CING）執行副總裁兼首席醫學官馬修·布拉姆斯於2024年4月3日參與了一筆交易。公告中未披露交易的具體細節，例如行動類型、狀態、股票數量、股票性質、交易價格和交易後持有量。這些信息對於投資者了解其投資的潛在影響以及內部人士對公司前景的信心至關重要。
有用
沒用
該公告為獨立文件：